Security record · archived quarter
BCRX
BioCryst Pharmaceuticals, Inc. · Healthcare · Biotechnology
2Tracked holders
0Δ holders
474.29KShares held
$3.95MReported value
+0New positions
−0Exits
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2026
Ownership over time
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 474.29K | $3.95M | n/a | n/a |
| Q2 2026 | 107 | +3 | 139.01M | $1.39B | +7 | −5 |
| Q1 2026 | 108 | +4 | 130.67M | $1.24B | +14 | −10 |
| Q4 2025 | 103 | -1 | 127.11M | $991.41M | n/a | −1 |
| Q3 2025 | 22 | +2 | 89.66M | $680.51M | +2 | −1 |
| Q2 2025 | 18 | +1 | 80.75M | $723.56M | +1 | n/a |
| Q1 2025 | 14 | +1 | 26.41M | $198.06M | +1 | n/a |
| Q4 2024 | 13 | -2 | 21.17M | $159.22M | n/a | −2 |
| Q3 2024 | 14 | +4 | 16.62M | $126.32M | +4 | n/a |
| Q2 2024 | 10 | n/a | 15.77M | $97.44M | n/a | n/a |
Who holds it · Q3 2026
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Assenagon Asset Management S.A. | 449.08K | -36.4% | $3.74M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 2 | Wealth Enhancement Advisory… | 25.21K | -61.3% | $208,974 | 0.0% | ▼ Trim | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 298 holders, 245.96M shares, $2.30B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
Frequently co-owned
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Aug 14
SC 13G/A: RA CAPITAL MANAGEMENT, L.P.
Aug 07
SC 13G: STATE STREET CORP
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q3 2026 ·
Methodology ·
Get this via the API